Search Results
Your search for ASCO,ASCO matches 22383 pages
Showing 1 - 50
Paolo Tarantino, MD, PhD, on HER2-Positive Metastatic Breast Cancer: Overall Survival by Genomic Profile
Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, reviews the results of a large clinicogenomic database study that looked at overall survival by genomic profile among patients with HER2-positive metastatic breast cancer. Patients with mutations in key DNA repair genes experienced a...
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic...
Renal Cell Carcinoma: FDA Approves Adjuvant Belzutifan With Pembrolizumab
Today, the U.S. Food and Drug Administration (FDA) approved the hypoxia-inducible factor-2 alpha inhibitor belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of adults with renal cell...
François-Clément Bidard, MD, PhD, on Advanced Breast Cancer With Emergent ESR1 Mutations: First-Line Option
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced...
Gerneiva Parkinson, MD, on Time on Systemic Therapy for Patients With HR-Positive Breast Cancer and a Pathogenic Variant
Gerneiva Parkinson, MD, of Stanford Cancer Institute, discusses time on treatment for systemic therapies among women with hormone receptor (HR)-positive breast cancer and a pathogenic variant in BRCA1, BRCA2, or PALB2 (Abstract 1096).
Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer
Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ovarian cancer (Abstract 10513).
Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer
Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone receptor (HR)-positive, HER2-negative breast cancer, including genomic testing and systemic therapy.
TP53 Mutation Acquisition Timing Influences Prognosis in MPNs, Study Finds
The timing of TP53 mutation acquisition carries important prognostic implications for patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes/MPN overlap disorders. Later emergence of the mutation is associated with significantly worse survival outcomes, according to a...
Machine Learning Model May Improve Accuracy of Liquid Biopsy Results
A machine learning model developed by researchers at the Johns Hopkins Kimmel Cancer Center filters out the biological noise in liquid biopsy samples, helping clinicians better match therapies to their patients’ tumors. These findings were published by Canzoniero et al in Clinical Cancer Research....
Head and Neck Cancer: HPV-DeepSeek May Identify Earlier Signs of Postoperative Recurrence
Researchers clinically validated a sensitive blood test as a whole-genome sequencing assay for detecting circulating tumor human papillomavirus (HPV) DNA in patients with HPV-associated head and neck cancer after surgery to search for residual disease as a sign of potential recurrence, according to ...
Urologic Surgeon Sworn in as AMA President
Willie Underwood III, MD, MSc, MPH, a urologic surgeon based in Buffalo, New York, was sworn on June 9 as the 181st President of the American Medical Association (AMA). Assuming the presidency at a pivotal moment for American health care, Dr. Underwood pledged during his inaugural address at AMA...
Can AI Provide an ‘Early Alert’ for Breast Cancer Before Diagnosis?
Three commercially available radiology artificial intelligence (AI) systems have shown the potential to flag early signs of breast cancer up to 6 years before a diagnosis, according to a Swedish study published by Hickman et al in Radiology. In a retrospective study, researchers tested three...
Elizabeth Smyth, MD, on New Data in Gastric/Gastroesophageal Cancers
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6...
Katharina C. Kaehler, MD, on Daromun in Resectable Locally Advanced Melanoma: Trial Updates
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional...
Dor Abelman, BS, on Multiple Myeloma: cfDNA WGS vs Plasma Proteomics for Minimally Invasive MRD Assessment
Dor Abelman, BS, of the University of Toronto, reviews results of a comparison of two minimally invasive measurable residual disease (MRD) assays—BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM)—in patients with multiple myeloma (Abstract 7546).
Jame Abraham, MD, FACP, on Update on the DESTINY-Breast05 Trial
Jame Abraham, MD, FACP, of Cleveland Clinic, provides an update on the DESTINY-Breast05 trial, which is an ongoing phase III trial investigating postneoadjuvant trastuzumab deruxtecan (T-DXd) as compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with residual...
Jame Abraham, MD, FACP, on First Results of the OPTIMA Trial in Breast Cancer: Expert Perspective
Jame Abraham, MD, FACP, of Cleveland Clinic, offers his thoughts on findings from OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), an international randomized controlled trial comparing chemotherapy decisions made with the Prosigna (PAM50) gene...
Krishnansu S. Tewari, MD, on Gynecologic Cancers: Expert Perspective on Major Data
Krishnansu S. Tewari, MD, of the University of California, Irvine, provides commentary on research presented in the oral abstract and rapid oral abstract sessions for gynecologic cancer, focusing on this year’s major trial data in endometrial, cervical, and ovarian cancers.
Rami Manochakian, MD, FASCO, on Updates on SCLC: No Longer Too Small to Ignore
Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, bispecific...
I’ve Beaten the Odds for Stage IV Lung Cancer
I learned that I had advanced stage non-small cell lung cancer (NSCLC) soon after a physician in the emergency department handed me the results of a computed tomography (CT) scan, which showed that I had lesions on my L3 and L4 vertebrae. The report stated that these lesions “were highly concerning ...
‘I’d Like to Agree With You…But Then We Would Both Be Wrong’
I am pleased to respond to the Letter to the Editor from Davis and Wolinsky printed in this issue of The ASCO Post, disagreeing with my views about screening for prostate cancer.In brief, the key points of my commentary were as follows: PSA is a useful tool in the management of prostate cancer;...
Prostate Cancer Screening Controversies
We read with interest the recent commentary by Derek Raghavan, MD, PhD, FACP, FASCO, FRACP, on ‘Prostate Screening Saved My Life’ Is That Really True in Most Cases?’ (The ASCO Post, April 25, 2026).1 As patient advocates, we agree with Dr. Raghavan on one important point: simplistic claims such as...
Physician-Scientist Albert B. Deisseroth, MD, PhD Dies at 84
Albert B. Deisseroth, MD, PhD, of Potomac, Maryland, passed away November 6, 2025, at Suburban Hospital in Bethesda, Maryland. Albert B. Deisseroth was born in 1941 in Middletown, New York. He attended the University of Rochester in New York where he earned his Bachelor’s degree. He stayed in...
2026 ASCO Breakthrough Meeting to Highlight New Advances in Liquid Biopsy, Metabolic Risks, and Tailored Therapies for Asian Populations
The ASCO Breakthrough meeting being held in Singapore this month will bring together global oncology professionals in Asia to discuss the latest cancer research advances across multiple disease sites that are shaping the future of patient care. New studies featured in the official Press Program...
ASCO Welcomes Proposal to Implement Electronic Prior Authorization Requirements for Covered Drugs in Federal Health Plans
The Centers for Medicare & Medicaid Services (CMS) has issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule. The proposal aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior...
ASCO Updates Policy Statement on 340B Drug Pricing Program
Early last month ASCO published an updated policy statement on the 340B Drug Pricing Program in JCO Oncology Practice.1 The update proposes a package of recommendations to expand practice eligibility, address potential abuses, and ensure the 340B program benefits the patients it was intended to...
Expanded Living Guidelines Program Ushers in a New Era for ASCO Guidelines
ASCO initiated its guideline program in 1993 and published the first guideline on colony stimulating factors in 1994.1 ASCO has evolved from publishing one or two guidelines annually to maintaining a robust library of over 118 guidelines with new guidelines added annually. Today, ASCO publishes...
Another Point of View: Reefer Madness!
The conclusions drawn from the study by Johnson et al1 appear overstated and should be interpreted with caution. In the study discussed in this issue of The ASCO Post, investigators compared breast and testicular cancer incidence trends in American states that had or had not legalized the use of...
‘The Science and Practice of Translation: Improving Cancer Outcomes Worldwide’
“Good morning, and welcome to the 62nd Annual Meeting of ASCO! ¡Buenos días, y bienvenidos a la sexagésima segunda reunión anual de ASCO! This is the world’s largest cancer research conference and the premier global platform for oncology innovation! But what brings us together today is not just...
Can Psychostimulants Treat Cancer-Related Fatigue?
A new meta-analysis provides updated evidence that methylphenidate-type psychostimulants—a class of medications that increase dopamine and norepinephrine availability in the brain—can provide meaningful relief for cancer-related fatigue. The study was published in the May 2026 issue of...
Daraxonrasib in KRAS-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment
Wolpin and colleagues have demonstrated in the global randomized Phase III RASolute 302 trial that daraxonrasib, an oral RAS(ON) inhibitor, nearly doubles median overall survival in previously treated metastatic pancreatic ductal adenocarcinoma, producing a median overall survival of 13.2 months...
Review of Breast Cancer News and Studies
Among the high-quality abstract presentations at ASCO and the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. The ASCO Post asked its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his selection and thoughts on some...
Weighing the Evidence Supporting Aspirin vs GLP-1RAs in Colorectal Cancer Prevention
A study by Jones et al offers a provocative contribution to the landscape of colorectal cancerprevention by directly comparing two pharmacologic strategies with markedly different historical roles in prevention (see sidebar on page 47).1 Aspirin has long served as the benchmark for primary...
A Burning Question: Can Wildfire Smoke Drive Cancer Risk?
Exposure to wildfire smoke was associated with significantly elevated risks of several cancers, including lung, colorectal, breast, bladder, and blood cancers, according to evidence from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial presented in a poster and press...
Geriatric Assessment Is the Future: Retiring Karnofsky and ECOG Performance Status in Modern Cancer Care
The purpose of this editorial is to challenge the continued reliance on Karnofsky Performance Status and Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status as primary tools for evaluating older adults with cancer. These measures have been in oncology practice for decades and...
Society of Gynecological Oncology Names 2026 President Matthew A. Powell, MD
Matthew A. Powell, MD, assumed the position of President of the Society of Gynecological Oncology (SGO) at the conclusion of the 2026 SGO Annual Meeting. Dr. Powell is the Ira C. and Judith Gall Distinguished Professor, Division of Gynecologic On-cology at Washington University School of Medicine...
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer
Four-year follow-up from the phase III RUBY clinical trial showed durable long-term benefit with front-line dostarlimab-gxly, a PD-1 blocker, plus carboplatin/paclitaxel in patients with mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) primary advanced or recurrent endometrial ...
Tafasitamab/Lenalidomide Combination vs R-CHOP in High-Risk DLBCL: Phase III frontMIND Trial
In patients newly diagnosed with high-risk large B-cell lymphoma, the addition of the CD19 monoclonal antibody tafasitamab plus the immunomodulatory drug lenalidomide (Tafa/Len) to standard therapy led to a 25% reduction in the risk of death or progression in the phase III frontMIND trial....
Digital Tool May Improve Patient Engagement in Oncology Clinical Trials
In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal (PEP). Alliance created PEP to...
New Research Links Low Alcohol Consumption to Elevated Health Risks
Researchers reported there was no protective net effect of any level of alcohol consumption on health observed in a new study published by George et al in the Journal of Studies on Alcohol and Drugs. Further, researchers reported that low levels of alcohol use may be associated with elevated health ...
GLP-1 RAs May Reduce Risk of Obesity-Related Cancers
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with a 41% lower risk of developing obesity-associated cancers in the short term for obese, nondiabetic patients, according to findings from an observational study published in Annals of Oncology. “Our study found that...
Christine Lovly, MD, PhD, FASCO, on Adjuvant Selpercatinib in RET Fusion–Positive Early-Stage NSCLC: Expert Perspective
Christine Lovly, MD, PhD, FASCO, of City of Hope, offers her thoughs on the findings of the LIBRETTO-432 trial, which found improved event-free survival with adjuvant selpercatinib after definitive therapy for patients with early-stage RET fusion–positive non–small cell lung cancer (NSCLC)...
Elizabeth McDonald, MD, PhD, on GLP-1 Agonists and Breast Cancer Incidence
Elizabeth McDonald, MD, PhD, of the University of Pennsylvania, discusses results from a retrospective cohort study that showed that the use of GLP-1 treatment was associated with a significantly lower incidence of breast cancer, after accounting for age, race, ethnicity, BMI, breast density, and...
Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4...
Suneel Kamath, MD, on Correlation Between Blood and Tissue Tumor Mutation Burden
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580).
Daneng Li, MD, on Tegavivint in Advanced HCC
Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015).
Joel W. Neal, MD, PhD, on the CHRYSALIS-2 Study in Atypical EGFR-Mutated Advanced NSCLC
Joel W. Neal, MD, PhD, of Stanford Cancer Institute, discusses updated overall survival data from cohort C of the CHRYSALIS-2 trial, which looked at first-line amivantamab plus lazertinib in previously untreated patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC)...
Music Therapy Noninferior to Cognitive Behavioral Therapy for Anxiety Among Cancer Survivors in Large Telehealth Trial
Guest Editor’s Note: Anxiety is a troubling symptom for many cancer survivors, yet treatment options remain limited. Although cognitive behavioral therapy (CBT) can be beneficial, barriers to access may limit its use. Music therapy, a nonpharmacologic intervention, has been shown to be effective in ...
Hannah L. Kenny, MD, and Joseph M. Curry, MD, on BCC of the Head and Neck: Neoadjuvant Cemiplimab
Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515).
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Agarwal et al, the phase III TALAPRO-3 trial has shown improved imaging-based progression-free survival with the addition of talazoparib to enzalutamide in patients receiving androgen-deprivation therapy for...
